Prostap DCS at a glance
Prostap DCS (leuprorelin):
- is the most widely used LHRH agonist worldwide1, with over 24 million patients treated since 19962
- benefits from 30 years of experience of leuprorelin3,4
- has been shown to provide long-term survival for prostate cancer patients, when combined with radiotherapy5
- has a well-established tolerability: majority of adverse events are related to androgen deprivation; most common events are hot flushes, increased sweating and decreased libido6-9*
- includes a device which is easy to administer1,2